RotateHydrogensLabels

OR9

(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol



Chemical Component Summary

Name(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Identifiers(6~{a}~{R})-6-methyl-5,6,6~{a},7-tetrahydro-4~{H}-dibenzo[de,g]quinoline-10,11-diol
FormulaC17 H17 N O2
Molecular Weight267.32
TypeNON-POLYMER
Isomeric SMILESCN1CCc2cccc-3c2[C@H]1Cc4c3c(c(cc4)O)O
InChIInChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
InChIKeyVMWNQDUVQKEIOC-CYBMUJFWSA-N

Chemical Details

Formal Charge0
Atom Count37
Chiral Atom Count1
Bond Count40
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB00714 
NameApomorphine
Groups
  • approved
  • investigational
DescriptionApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919]
Synonyms
  • (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diol
  • (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
  • Apomorfina
  • Apomorphin
  • Apomorphine hydrochloride
Brand Names
  • Movapo
  • Apokyn
  • Kynmobi
IndicationApomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.[L13919,L13922]
Categories
  • Alkaloids
  • Anti-Parkinson Agents (Dopamine Agonist)
  • Anti-Parkinson Drugs
  • Antidepressive Agents
  • Aporphines
ATC-Code
  • G04BE07
  • N04BC07
CAS number58-00-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Dopamine D4 receptorMGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLA...unknownagonist
Dopamine D2 receptorMDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF...unknownagonist
Dopamine D3 receptorMASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV...unknownagonist
Dopamine D5 receptorMLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLL...unknownagonist
Dopamine D1 receptorMRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIR...unknownagonist
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDFIKFIP
PubChem6005
ChEBICHEBI:48538
ChEMBLCHEMBL53
PharosCHEMBL53